Nalaganje...
Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Semaglutide, a newly once-weekly glucagon like peptide-1 (GLP-1) receptor agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 diabetes mellitus (T2DM). This meta-analysis was conducted to evaluate the clinical efficacy and safety of semaglutide in T...
Shranjeno v:
| izdano v: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5994433/ https://ncbi.nlm.nih.gov/pubmed/29915538 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.00576 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|